Vigil Neuroscience
VIGL
VIGL was delisted on the 4th of August, 2025.
47 hedge funds and large institutions have $125M invested in Vigil Neuroscience in 2022 Q1 according to their latest regulatory filings, with 47 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
63.18% more ownership
Funds ownership: 0% → 63.18% (+63%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
+$77M |
| 2 |
NV
Northpond Ventures
Bethesda,
Maryland
|
+$55.6M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$28.5M |
| 4 |
AG
Artal Group
Luxembourg
|
+$14.8M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$8.14M |
Top Sellers
VIGL Hedge Fund Activity: Q1 2022 in Review
47 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Vigil Neuroscience (VIGL) for Q1 2022, worth a combined $125M.
Buyers outnumbered sellers: 47 funds opened new VIGL positions and 0 closed out — a net gain of 47 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Atlas Venture Life Science Advisors, opening a new position worth an estimated $77M.
- 47 institutional investors held Vigil Neuroscience (VIGL) as of Q1 2022, up from 0 in Q4 2021.
- Funds reported $125M of Vigil Neuroscience stock for Q1 2022.
- 47 funds opened new Vigil Neuroscience positions in Q1 2022 and 0 closed out, a net change of +47 holders.
- The largest Vigil Neuroscience buyer in Q1 2022 was Atlas Venture Life Science Advisors, an estimated $77M added.
Based on aggregated 13F filings for Q1 2022.